Holen Sie sich die Stockscreener-App
5.82
0.17%
0.01
Schlusskurs vom Vortag:
$5.81
Offen:
$6.16
24-Stunden-Volumen:
2,483
Relative Volume:
0.29
Marktkapitalisierung:
$80.82M
Einnahmen:
$57.94M
Nettoeinkommen (Verlust:
$-2.34M
KGV:
-34.93
EPS:
-0.1666
Netto-Cashflow:
$3.82M
1W Leistung:
+1.04%
1M Leistung:
+1.75%
6M Leistung:
-14.16%
1J Leistung:
-33.94%
1-Tages-Spanne:
$5.82
$6.16
1-Wochen-Bereich:
$5.55
$6.16
52-Wochen-Spanne:
$5.50
$8.98
Champions Oncology Inc Stock (CSBR) Company Profile
Firmenname
Champions Oncology Inc
Sektor
Branche
Telefon
410-369-0365
Adresse
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.82 | 80.82M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-12 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-11-18 | Eingeleitet | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Aktie (CSBR) Neueste Nachrichten
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
CSBR Q4'25 Earnings: revenue estimate is 12.89M USD - TradingView
Champions Oncology (CSBR) Holds Steady Near Support as Traders Await DirectionIchimoku TK Cross - dars.gov.et
IMMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
(CSBR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Enterprise value to revenue forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight - The AI Journal
ENGN Q1 2026 Earnings: Loss Narrows as EPS Beats ExpectationsFree Cash Flow Trends - dars.gov.et
Price to sales forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Price to sales forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
“Publish or Perish”: Should Science Rethink Success Metrics? - Technology Networks
Price to earnings forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Price to book forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Price to earnings forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR) - TradingView
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology to Announce First Quarter Financial Results on Monday, September 16, 2019 - ACCESS Newswire
Registration Opens for JADPRO Live 2026: Advanced Practitioners Gather in the Heartland to Champion High-Quality Cancer Care - Yahoo! Finance Canada
Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis - TradingKey
LAR Q1 2026 Earnings: EPS Misses Estimates, Revenue Not Reported, Stock DeclinesEBITDA Estimate Trend - dars.gov.et
Price-Driven Insight from (CSBR) for Rule-Based Strategy - Stock Traders Daily
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
TXNM Energy, Inc. Files Form 8-K With SEC: Company Information, Stock, and Contact Details - Minichart
Hong Kong IPO Boom Faces Performance Challenges as Post-Listing Returns FadeEarnings Weakness Phase - newsline.com
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation? (LLY:NYSE) - Seeking Alpha
(CSBR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
LCTX Q1 2026 Earnings: EPS Misses Estimates as Cell Therapy Pipeline AdvancesEarnings Weakness Phase - dars.gov.et
Check For Cancer Champion Dr. Ryan Schoenfeld Has a Vision For Earlier Detection - ACCESS Newswire
Check for Cancer Champion Dr. Ryan Schoenfeld has a vision for earlier detection - Aflac Newsroom
Vail Resorts (MTN) Edges Higher as Ski Season Momentum BuildsModified Schiff - newsline.com
AQU PE Ratio & Valuation, Is AQU Overvalued - Intellectia AI
CSBR Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Edges HigherBook Value Growth - newsline.com
CSBR Q1 2026 Earnings: Earnings Miss Hides Underlying Progress in Oncology PlatformCFO Commentary Report - newsline.com
Champions Oncology Q1 2026 Earnings: EPS Miss of 121.79% Weighs on Results Despite Modest Stock Gain - newsline.com
CGI Inc. (GIB) Faces Pressure: Stock Drops Nearly 4% as Support Levels ApproachPre-Earnings Momentum - newsline.com
CSBR Technical Analysis & Stock Price Forecast - Intellectia AI
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - Yahoo Finance UK
CSBR Q1 2026 Earnings: EPS Misses Estimates, Stock Gains SlightlyConsensus Beat Rate - dars.gov.et
(CSBR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Medidata Champions Collaborative Scientific Advancement at ASCO with New Research on Oncology Protocol Optimization and CAR T Efficacy - marketscreener.com
Champions Oncology Inc. (CSBR) Q1 2026 Earnings: Earnings Miss Estimates as EPS Falls to -$0.02Special Dividend Alert - The Legal Advocate
Finanzdaten der Champions Oncology Inc-Aktie (CSBR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):